Abstract
Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term PMF was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).
| Original language | English (US) |
|---|---|
| Title of host publication | Rare Hematological Malignancies |
| Publisher | Springer US |
| Pages | 29-49 |
| Number of pages | 21 |
| ISBN (Print) | 9780387737430 |
| DOIs | |
| State | Published - 2008 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Primary myelofi brosis. / Tefferi, Ayalew.
Rare Hematological Malignancies. Springer US, 2008. p. 29-49.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Primary myelofi brosis
AU - Tefferi, Ayalew
PY - 2008
Y1 - 2008
N2 - Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term PMF was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).
AB - Myelofibrosis (MF) in the context of a myeloproliferative disorder is a clinicopathologically defined entity characterized by anemia, marked splenomegaly, constitutional symptoms, leukoerythroblastosis (i.e., the presence of immature granulocytes and nucleated red blood cells), dacryocytosis (i.e., presence of teardrop-shaped red blood cells), and a bone marrow that displays dysplastic megakaryocyte hyperplasia, granulocyte proliferation, and reticulin and/or collagen fibrosis (1). Disease presentation could be either de novo (primary MF; PMF) or preceded by either polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF). PMF is also known by many other names (Table 2.1), including chronic idiopathic myelofibrosis (CIMF), the term used by the World Health Organization (WHO) system for classification of myeloid neoplasms (2). However, the use of the term PMF was recently endorsed by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (3).
UR - http://www.scopus.com/inward/record.url?scp=84888400175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888400175&partnerID=8YFLogxK
U2 - 10.1007/978-0-387-73744-7_2
DO - 10.1007/978-0-387-73744-7_2
M3 - Chapter
AN - SCOPUS:84888400175
SN - 9780387737430
SP - 29
EP - 49
BT - Rare Hematological Malignancies
PB - Springer US
ER -